Method for treating connective tissue disorders

• US 5,226,914 A
• Filed: 11/16/1990
• Issued: 07/13/1993
• Est. Priority Date: 11/16/1990
• Status: Expired due to Term

• Current Assignee: Mesoblast International Srl
• Original Assignee: Case Western Reserve University
• Inventors: Caplan, Arnold I., Haynesworth, Stephen E.
• Primary Examiner(s): Green, Randall L.
• Assistant Examiner(s): BRITTINGHAM, DEBRA
• Application Number:
  US07/614,912
• Time in Patent Office: 970 Days
• Field of Search: 623/11, 623/12, 623/16, 623/18, 623/66, 424/422, 424/423, 424/95, 435/240.243, 435/240.2, 530/838, 530/840
• US Class Current: 435/325
• CPC Class Codes: A61F 2/28 Bones joints A61F2/30
• CPC Class Codes: A61F 2/30756 Cartilage endoprostheses A61F2/3603 takes precedence
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 31/005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2533/18 Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
• CPC Class Codes: C12N 5/0068 General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: Y10S 530/838 Marrow; spleen
• CPC Class Codes: Y10S 530/84 Bones; tendons; teeth; cartilage
• CPC Class Codes: Y10S 623/919 Bone
• CPC Class Codes: Y10S 623/92 Method or apparatus for preparing or treating prosthetic

Abstract

The present invention is directed to various processes and devices for utilizing isolated and culturally expanded marrow-derived mesenchymal cells (i.e. mesenchymal stem cells) for treating skeletal and other connective tissue disorders.

Claims

1. A method for repairing connective tissue damage comprising:

a) providing culturally expanded purified human marrow-derived mesenchymal cells which have been isolated from a bone marrow specimen by adding the bone marrow specimen to a medium which contains factors which stimulate mesenchymal stem cell growth without differentiation and allows, when cultured, for selective adherence of only the mesenchymal stem cells to a substrate surface; and

,

b) applying the culturally expanded purified human marrow-derived mesenchymal cells to an area of connective tissue damage under conditions suitable for differentiating the cells into connective tissue cells necessary for repair.

2. The method of claim 1 wherein the culturally expanded purified marrow-derived mesenchymal cells are applied to the area of connective tissue damage by in vivo administration.

3. The method of claim 1 wherein the culturally expanded purified marrow-derived mesenchymal cells are applied to the area of connective tissue damage by injection.

4. The method of claim 1, further comprising the step of adding to said mesenchymal stem cells a factor which stimulates differentiation of the marrow-derived mesenchymal cells into osteocytes.

5. A method for enhancing implantation of a prosthetic device in connective tissue comprising:

a) providing culturally expanded purified human marrow-derived mesenchymal cells which have been isolated from a bone marrow specimen by adding the bone marrow specimen to a medium which contains factors which stimulate mesenchymal stem cell growth without differentiation and allows, when cultured, for selective adherence of only the mesenchymal stem cells to a substrate surface;

b) adhering said culturally expanded purified human marrow-derived mesenchymal cells on to a prosthetic device; and

,

c) implanting the prosthetic device containing the culturally expanded purified marrow-derived mesenchymal cells under conditions suitable for differentiating the cells into connective tissue.

6. The method of claim 5 further comprising the steps of adding to said marrow-derived mesenchymal cells a factor which stimulates differentiation of the marrow-derived mesenchymal cells into osteocytes.

7. A method for repairing connective tissue damage comprising the steps of:

a) providing a bone marrow specimen containing human mesenchymal stem cells and bone pieces;

b) adding the bone marrow specimen to a medium which contains factors which stimulate mesenchymal stem cell growth without differentiation and allows, when cultured, for the selective adherence of only the mesenchymal stem cells to a substrate surface;

c) separating the bone pieces from the bone marrow medium mixture;

d) dissociating the marrow cells into single cells;

e) culturing the dissociated marrow cells in the bone marrow medium mixture;

f) separating the non-adherent matter from the substrate surface thereby producing isolated culturally expanded mesenchymal stem cells; and

,

g) applying the culturally expanded purified mesenchymal stem cells to the area of connective tissue damage under conditions suitable for differentiating the cells into the type of connective tissue cells necessary for repair.

8. The method of claim 7 wherein the culturally expanded purified mesenchymal stem cells are applied to the area of connective tissue damage by in vivo administration.

9. The method of claim 7 wherein the culturally expanded purified mesenchymal stem cells are applied to the area of connective tissue damage by injection.

10. The method of claim 7 further comprising the step of adding to said mesenchymal stem cells a factor which stimulates differentiation of the mesenchymal stem cells into osteocytes.

11. The method of claim 7 wherein said medium is comprised of BGJ_b medium with 10% fetal bovine serum.

12. The method of claim 7 wherein said medium is comprised of F-12 nutrient mixture.

13. A method for enhancing implantation of a prosthetic device in a connective tissue comprising:

a) providing a bone marrow specimen containing human mesenchymal stem cells and bone pieces;

b) adding the bone marrow specimen to a medium which contains factors which stimulate mesenchymal stem cell growth without differentiation and allows, when cultured, for selective adherence of only the mesenchymal stem cells to a substrate surface;

c) separating the bone pieces from the bone marrow medium mixture;

d) dissociating the marrow cells into single cells;

e) culturing the dissociated marrow cells in the bone marrow medium mixture;

f) separating non-adherent matter from the substrate surface thereby producing isolated culturally expanded mesenchymal stem cells;

g) adhering said culturally expanded purified mesenchymal stem cells on to a prosthetic device; and

,

h) implanting the prosthetic device containing the culturally expanded purified mesenchymal stem cells under conditions suitable for differentiating the cells into skeletal tissue.

14. The method of claim 13, further comprising the steps of adding to said mesenchymal stem cells a factor which stimulates differentiation of the mesenchymal stem cells into osteocytes.

15. The method of claim 13, wherein said medium is comprised of BGJ_b medium with 10% fetal bovine serum.

16. The method of claim 13, wherein said medium is comprised of F-12 nutrient mixture.

17. A method for generating a hematopoietic stem cell reserve comprising:

a) providing human marrow-derived mesenchymal stem cells that have been isolated, purified and culturally expanded;

b) applying the isolated, purified and culturally expanded marrow-derived human mesenchymal stem cells to a porous carrier;

c) implanting the porous carrier containing the mesenchymal stem cells into a host patient;

d) allowing for a sufficient period of time for inducement of hematopoietic stem cells present in the host patient into the porous carrier; and

e) harvesting the hematopoietic stem cells present in the porous carrier.

18. The method of claim 17, wherein said porous carrier comprises about 60% hydroxyapatite and about 40% tricalcium phosphate.

19. A method for generating a human hematopoietic stem cell reserve comprising:

a) providing a bone marrow specimen containing human marrow-derived mesenchymal stem cells and bone pieces;

b) adding the bone marrow specimen to a medium which contains factors which stimulate the human marrow-derived mesenchymal stem cells to grow without differentiation and allows, when cultured, for selective adherence of only the marrow-derived human mesenchymal stem cells to a substrate surface;

c) separating the bone pieces from the bone marrow medium mixture;

d) dissociating the marrow cells into single cells;

e) culturing the dissociated marrow cells in the bone marrow medium mixture;

f) separating non-adherent matter from the substrate surface, thereby producing isolated culturally expanded human marrow-derived mesenchymal stem cells;

g) applying the culturally expanded human marrow-derived mesenchymal stem cells to a porous carrier;

h) implanting the porous carrier containing the culturally expanded marrow-derived mesenchymal cells into a host patient;

i) allowing for a sufficient period of time for inducement of hematopoietic stem cells present in the host patient into the porous carrier; and

,

j) harvesting the hematopoietic stem cells collected by the porous carrier.

20. The method of claim 19, wherein said porous carrier is comprised of about 60% hydroxyapatite and about 40% tricalcium phosphate.

21. The method of claim 19, wherein said medium is comprised of BGJ_b Medium with 10% fetal bovine serum.

22. The method of claim 19, wherein said medium is comprised of F-12 Nutrient Mixture.

23. A method for repairing connective tissue damage comprising:

a) providing a bone marrow specimen containing human mesenchymal stem cells;

b) adding the bone marrow specimen to a medium thereby producing a bone marrow specimen-medium mixture, wherein said medium contains factors that stimulate mesenchymal stem cell growth without differentiation and allows, when cultured, for selective adherence of only the mesenchymal stem cells to a substrate surface;

c) adding the bone marrow specimen-medium mixture to a density gradient which separates cells into low, medium and high density cell fractions based on differences in density;

d) removing the low density cell fraction from the density gradient;

e) adding the low density cell fraction to the medium used in step (b) to produce a low density cell fraction-medium mixture;

f) culturing the low density cell fraction-medium mixture, thereby selectively adhering only the mesenchymal stem cells to the substrate surface;

g) removing any non-adherent matter from substrate surface;

h) removing the remaining adherent mesenchymal stem cells from the substrate surface with a releasing agent, thereby allowing for the isolated mesenchymal stem cells to be recovered; and

,

i) applying an culturally expanded purified human marrow-derived mesenchymal cells to the area of connective tissue damage under conditions suitable for differentiating the cells into connective tissue necessary for repair.